GlassScriptPhysician profile
Stacy L Donlon
NPI 1346403383
$612,796.67
in general payments reported to CMS, 2019-2025
24 companies · $103K in 2025
The $103K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $59K · 2021: $50K · 2022: $100K · 2023: $81K · 2024: $81K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $205K · Travel and Lodging: $25K · Consulting Fee: $25K · Food and Beverage: $9,025 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $204,967.00 |
| Travel and Lodging | $25,406.46 |
| Consulting Fee | $25,173.00 |
| Food and Beverage | $9,025.31 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $247,199.04 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $113,429.35 | 2019-2025 | |
| Biogen, INC. | $80,646.96 | 2019-2025 | |
| Tg Therapeutics, INC. | $40,858.53 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $35,736.52 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $34,238.22 | 2019-2025 | |
| Genentech USA, INC. | $29,677.70 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Horizon Therapeutics Plc | $17,351.46 | 2021-2022 | |
| Celgene Corporation | $11,624.18 | 2020-2025 | Zeposia |
| Genentech, INC. | $1,550.93 | 2021-2025 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $129.78 | 2019-2024 | Ultomiris |
| Neurocrine Biosciences, INC. | $77.55 | 2019-2020 | |
| Amgen INC. | $64.78 | 2020-2025 | Uplizna |
| Lundbeck LLC | $46.18 | 2020 | |
| Allergan, INC. | $30.69 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $27.71 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $26.29 | 2019-2020 | |
| Abbvie INC. | $22.39 | 2021 | |
| Acorda Therapeutics, INC | $21.76 | 2019 | |
| Bausch Health US, LLC | $20.37 | 2019 | |
| Acadia Pharmaceuticals INC | $16.28 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Donlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.